Protections of transcription factor BACH2 and natural product myricetin against pathological cardiac hypertrophy and dysfunction.

Jiang, Xueli; Cao, Mengying; Wu, Jian; Wang, Xiaolin; Zhang, Guoping; Yang, Chunjie; Gao, Pan; Zou, Yunzeng

Jiang, Xueli; Cao, Mengying; Wu, Jian; Wang, Xiaolin; Zhang, Guoping; Yang, Chunjie; Gao, Pan; Zou, Yunzeng.

Afiliação

Jiang X; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Cao M; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Wu J; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Wang X; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Zhang G; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Yang C; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Gao P; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Zou Y; Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai, China.

Front Physiol ; 13: 971424, 2022.

Article em En | MEDLINE | ID: mdl-36105283

Palavras-chave

AKAP65; BACH21; cardiac hypertrophy2; heart failure3; myricetin4

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Physiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China